Skip to main content

Table 5 Survival analyses

From: 18F-FDG PET/CT-based metabolic metrics in recurrent tumors of ovarian clear cell carcinoma and their prognostic implications

Univariate analysis
Variables P (OS) P (PRS)
 Stage at initial diagnosis (Early Vs. Late) 0.006* 0.009*
 Platinum response (Sensitive Vs. Resistant) < 0.001* 0.051
 Type of second-line treatment (SCS + chemo Vs. Chemo) 0.012* 0.021*
 Number of relapsed lesions (Single Vs. Multiple) 0.008* 0.019*
 Peritoneal carcinomatosis (No Vs. Yes) 0.001* < 0.001*
 SUVmax (Low Vs. High) 0.768 0.774
 MTV (Low Vs. High) 0.083 0.128
 TLG (Low Vs. High) 0.079 0.112
 MTV40 (Low Vs. High) 0.141 0.091
 TLG40 (Low Vs. High) 0.095 0.108
 MTV50 (Low Vs. High) 0.129 0.098
 TLG50 (Low Vs. High) 0.095 0.108
 MTV60 (Low Vs. High) 0.129 0.098
 TLG60 (Low Vs. High) 0.044* 0.031*
Multivariate analysis
Variables OS PRS
HR 95% CI P value HR 95% CI P value
 Stage at initial diagnosis 1.034 0.252–4.2 0.963 2.1 0.6–7.3 0.224
 Platinum response 16.5 3.2–85.2 0.001* / / /
 Type of second-line treatment 1.085 0.5–24.8 0.959 0.3 0.1–5.4 0.424
 Number of relapsed lesions 1.1 0.3–4.2 0.862 2.8 0.7–10.8 0.140
 Peritoneal carcinomatosis 12.1 2.4–61.1 0.002* 7.7 2.2–27.3 0.002*
 TLG60 4.8 1.2–18.7 0.024* 2.0 0.6–6.7 0.254
  1. †Metabolic parameters were dichotomized using the median number as cut-off value
  2. *P values with statistical significance were denoted by bold characters in underline 
  3. Abbreviations: OS Overall Survival, PRS Post-Relapse Survival, SCS Secondary cytoreduction surgery, Chemo Chemotherapy, SUVmax Maximum Standardized Uptake Value, MTV Metabolic Tumor Volume, TLG Total Lesion Glycolysis, HR Hazard Ratio, CI Confidence Interval